MCM
BMY.RT

McRae Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

McRae Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100,892
Closed -$70K – 109
2020
Q4 		$70K Sell
100,892
-425
-0.4% -$905 0.02% 101
2020
Q3 		$228K Buy
101,317
+100
+0.1% +$286 0.08% 86
2020
Q2 		$362K Sell
101,217
-100
-0.1% -$361 0.14% 65
2020
Q1 		$385K Buy
101,317
+200
+0.2% +$659 0.19% 60
2019
Q4 		$304K Buy
+101,117
New +$263K 0.11% 73

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

McRae Capital Management's BMY.RT Position: Q1 2021 in Review

McRae Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 100,892 shares — an estimated $70K sold.

McRae Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $385K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • McRae Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • McRae Capital Management sold 100,892 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $70K.
  • McRae Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • McRae Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $385K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on McRae Capital Management's 13F filing for Q1 2021, filed 11 May 2021.